A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.
2022 proved to be a year where the continuation of all things COVID-19 played an important role through much of the year. With discussions around vaccines, Long COVID, and whether it would become endemic or episodic, the virus dominated much of the news in infectious disease.
Other ID topics such as antimicrobial resistance and C difficile also proved to be important topics people wanted to learn more about.
Listed below are some of our most popular video interviews from this year.
The Potential Benefits of the Novavax COVID-19 Vaccine
When the company submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373, back in February, William Schaffner,MD, medical director of the National Foundation for Infectious Diseases (NFID) and Donald Alcendor, PhD, assistant professor of Cancer Biology Meharry Medical College, offered some insights and perspective on the vaccine.
Axcella Therapeutics chief medical officer Margaret Koziel, MD, discussed the stage 2a clinical trial for their novel long covid treatment.
Building Momentum for the Pasteur Act
Amanda Jezek, senior vice president of public policy and government relations at IDSA, offered some insights on the inroads being made in Congress for this antimicrobial resistance legislation.
COVID-19 Will 'Not Become Endemic But Episodic’
Robert Gottlieb, MD, PhD, FACC, Baylor Heart and Vascular Hospital, foresaw the possibility of the virus not becoming endemic but episodic.
Looking Beyond C difficile: The Potential of the Gut Microbiome
Elizabeth Garner, MD, speculated the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.